Jeffrey Paul, PhD
Research Interests: For the past 15 years, Dr. Paul's research interests have been focused on clinical pharmacology aspects of neuropharmacology and the early clinical development of experimental therapeutics. Specifically, his current interest is in developing tools for the de-risking and early decision making for neurological, psychiatric, and pain experimental therapeutics using translation, experimental medicine, and biomarker evaluations. As a clinical pharmacologist, he looks to integrate basic pharmacology principles and clinical approaches into furthering the value of the clinical pharmacology discipline. The platforms that he uses include pharmacogenomics, pharmacometrics, pharmacokinetics/pharmacodynamics, translation/biomarkers, and precision medicine (where possible) in early clinical drug development.
Background: Dr. Paul is a clinical pharmacology consultant to the pharmaceutical industry, focusing his practice on the early clinical development of drugs for CNS and pain. Dr. Paul has spent nearly 30 years in pharmaceutical R&D, including discovery, and phase 1 through 4 clinical development phases. He has global clinical and regulatory experience, especially in Europe and Japan. He has worked at Berlex, Pfizer (formerly Wyeth), and Astellas at the executive director/assistant VP level. Dr. Paul has an adjunct faculty appointment at Drexel Medical College (Philadelphia) where he teaches in the graduate Drug Discovery and Development, Neuropharmacology courses, as well as serving as course director for Clinical Pharmacology (i.e Pharmacotherapy) in Drexel’s Clinical Research for Health Professionals Program. Dr. Paul is also active in promoting translation medicine as a member of the Executive Committee of Translation, Clinical Pharmacology Division of Am. Soc. for Pharmacology & Experimental Therapeutics (ASPET), and the Am. Soc for Clinical Pharmacology and Therapeutics (ASCPT).